A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
A phase 3 trial testing TQB2102 in HR-positive / HER2-negative breast cancer, active and no longer recruiting.
Overview
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer is a phase 3 interventional study registered as NCT06561607, led by Chia Tai Tianqing Pharmaceutical, and active but no longer recruiting when checked on 2026-09-11. Official title: A Randomised, Open, Parallel-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer. Planned enrolment is 542 participants (estimated). The study started in 2024-10-11 and primary completion is expected in 2027-01. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialTo Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialClinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialA Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.